SMS Pharmaceuticals Limited

As of June 30, 2026, SMS Pharmaceuticals Limited carries a market capitalization of 38.73B, placing it among publicly traded companies globally. Its enterprise value stands at 38.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SMS Pharmaceuticals Limited has 93.65M shares outstanding.

As of June 30, 2026, SMS Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 36.83.

As of June 30, 2026, SMS Pharmaceuticals Limited trades at an EV/EBITDA multiple of 22.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 38.73B versus a market cap of 38.73B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.54M in revenue per employee across its workforce of 1,977.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, SMS Pharmaceuticals Limited recorded 299.89M in income tax expense. That works out to an effective tax rate of 25.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.19B, leaving 1.02B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, SMS Pharmaceuticals Limited's stock has gained approximately 47.67% over the past 52 weeks. The 50-day moving average sits at 415.58, while the 200-day moving average is 385.81.

Over the twelve months ended June 30, 2026, SMS Pharmaceuticals Limited generated 8.98B in revenue and converted that into 1.02B in net income, yielding earnings per share of 11.23. EBITDA reached 1.73B, while operating income came in at 1.33B.

Over the twelve months ended June 30, 2026, SMS Pharmaceuticals Limited posted a gross margin of 34.30, reflecting its pricing power and cost economics. The operating margin of 14.78 and net profit margin of 11.41 provide insight into operational efficiency.

SMS Pharmaceuticals Limited's most recent stock split took place on December 17, 2015 with a 1:10 split ratio.